All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 27, 2021
Home » Blogs » BioWorld MedTech Perspectives » Corporate greed vs. the American Dream

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Corporate greed vs. the American Dream

July 15, 2014
By Amanda Pedersen
No Comments

The Statue of Liberty, an iconic symbol of the American Dream.
The Statue of Liberty, an iconic symbol of the American Dream.

In 2004 my hometown lost its largest employer to corporate greed. I was a young reporter for the local newspaper, The Register-Mail, when Maytag closed its doors in 2004, forcing roughly 1,600 workers in Galesburg, Illinois and surrounding towns out of their jobs. Most hurtful to the community was the factory’s reason for shutting down: Maytag moved to Mexico to take advantage of cheap labor.

Galesburg has never been the same and a lot of people there are still struggling financially and they feel betrayed by the broken promise of the American Dream.

Now I see a similar trend happening in the medical device industry. When I learned a couple weeks ago that Medtronic plans to buy Covidien, a decision largely driven by the desire to lower its tax burden, I got the same sick-to-the-stomach feeling I had 10 years ago when I listened to dozens of scared factory workers talk about their uncertain future.

Medtronic buying Ireland-based Covidien will take options off the table for young companies struggling to bring new products to market. The med-tech giant has tried to prove its loyalty to the U.S market by promising to invest $10 billion over the next 10 years through early stage VC investments, acquisitions, and R&D in the U.S. but that has done little to convince critics that the company has the U.S. economy’s best interests at heart.

Sure, this grand scheme to save on corporate taxes will actually generate a ton of other U.S. taxes, but Medtronic’s shareholders will have to foot that bill. That’s because when stock holders exchange their Medtronic shares for shares in the “new” Ireland-based Medtronic, it will be treated like a sale.

There are some bright sides to the proposed merger, such as increased scale in the face of hospital and payer consolidation in the U.S. and portfolio breadth, which is increasingly important in this post-Affordable Care Act environment.

And Medtronic’s executives have tried to sugarcoat the deal as a business strategy rather than tax inversion. I don’t disagree that there are strategic benefits to be realized. But if that was truly the driving force behind this $42.9 billion mega-deal, why is the agreement contingent on there being no new laws or regulatory actions passed that would make such inversion deals illegal or prevent Medtronic from capitalizing on Covidien’s lower tax rate?

Lee Schafer, a business columnist at the Star Tribune, a Minneapolis-based newspaper, has covered the deal from a few different angles. I imagine Schafer, being based in Medtronic’s backyard (or maybe it’s the other way around), has witnessed a similar state of dejection that I witnessed 10 years ago in the struggling, Midwestern factory town where I grew up.

Schafer hinted at those boiling emotions in a recent column in which he tried to offer the story from the company’s point of view. “But it seems clear that [Medtronic] underestimated just how mad individual shareholders would get once they learned they faced a capital-gains tax from the transaction and perhaps how many folks in our community felt betrayed that one of ours was leaving for tax reasons.”

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 26.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing